# Quinnova Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quinnova-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.quinnova.com
- Total disclosed funding: $30M
- Latest round: Series B (Oct 28, 2009)
- Investors on record: 5

## About

Quinnova Pharmaceuticals Inc. is a U.S.-based company focused on developing and distributing performance-enhancing supplements, including SARMs, peptides, and nootropics, tailored for athletes and health-conscious consumers.Founded in 2003, Quinnova Pharmaceuticals Inc. specializes in performance-enhancing supplements. In December 2013, the company was acquired by Everett Laboratories. The firm operates out of the United States, focusing primarily on the North American and European markets. No notable pivots in business strategy have been reported.Quinnova Pharmaceuticals specializes in the development and distribution of performance-enhancing supplements, including SARMs (Selective Androgen Receptor Modulators), peptides, and nootropics. Their core products support muscle growth, fat loss, and cognitive enhancement, catering to bodybuilders, athletes, and individuals seeking to optimize their performance. Products are available through direct-to-consumer channels and partnerships with retailers.Quinnova Pharmaceuticals generates revenue through direct sales of its supplement products, primarily targeting individual consumers and fitness enthusiasts. Sales are facilitated through their online platform, offering products like MK-677 and CJC 1295 Ipamorelin. The company also engages in partnerships with retailers. Their pricing strategy targets a diverse clientele, offering products for single purchases or bulk orders, alongside potential subscription services.Quinnova Pharmaceuticals plans to expand its product line and market reach. Following the acquisition in December 2013, recent funding will support the development of new supplements and entry into additional global markets. Specific upcoming products and their release dates have not been disclosed, but the focus will remain on enhancing their offerings in existing territories, particularly North America and Europe.

## Funding rounds

- Series B, Oct 28, 2009, $17M — Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. BioHealth Partners
- Series A, Nov 28, 2006, $13M — H.I.G. Capital, Thomas, McNerney & Partners, Omnivest Group

## Investors

- H.I.G. Capital (https://capitalatlas.ai/funds/h-i-g-capital) — Series A
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series A, Series B
- Omnivest Group — Series A
- Safeguard Scientifics (https://capitalatlas.ai/funds/safeguard-scientifics) — Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B